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BACKGROUND: Phase II data from the BELOB trial indicated that the
combination of bevacizumab and lomustinemight produce an overall survival
(OS) benefit compared with either monotherapy for patients with first
progression of a glioblastoma. The primary objective of the phase III part of
EORTC 26101 is to investigate whether the addition of bevacizumab to
lomustine improves overall OS in patients with first progression of a glioblas-
tomacompared to treatmentwith lomustine alone.METHODS: Patientswith
progressive disease after standard chemo-radiotherapy with temozolomide at
least 3months off the concomitant part were randomized 2:1 between lomus-
tine 90 mg/m2 (cap. 160 mg)mg every sixweeks plus 10 mg/kg bevacizumab
every two weeks and lomustine single agent 110 mg/m2 (cap. 200 mg) every
six weeks followed by best investigators choice at further progression. In the
absence of hematological toxicity . grade 1 during the first cycle in the com-
bination arms, the dose of lomustine could be escalated to 110 mg/m2 (cap
200 mg) in the second cycle. Neuroimaging according to a standard protocol
was assessed locally and centrally. RESULTS: A total of 437 (288 and 149, re-
spectively) patients were included. Median number of treatment cycles was 1
in the lomustine arm and 3 in the combination arm. With 329 OS events
(75.3%) OS was not superior in the combination therapy arm (hazard ratio
(HR) 0.95 (confidence interval (CI) 0.74, 1.21), p ¼ 0.650, analyses stratified
by EORTC online randomization system), whereas locally assessed
progression-free survival (PFS) was longer with the addition of bevacizumab
to lomustine (HR 0.49 (CI 0.39, 0.61). Median efficacy outcomes were: OS
9.1 (8.1, 10.1) versus 8.6 (7.6, 10.4) months and PFS 4.2 (3.7, 4.3) versus
1.5 (1.5, 2.5)months in the combination armversus the lomustine arm respec-
tively. Toxicitywas in the expected rangewithmore events in the combination
arm being also longer on treatment. Crossover to bevacizumab occurred in
35.5% of patients in the control arm; whereas 19% of patients in the combi-
nation arm continued bevacizumab at progression. CONCLUSIONS:
Bevacizumab treatment in patientswith progressive glioblastomadespite pro-
longed PFS does not confer a survival advantage. The future challenge is to
identify those patients deriving benefit from that treatment.
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